An Open Label Trial of STRIBILD(TM) (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naive HIV-2 Infected Adults in Dakar, Senegal

Trial Profile

An Open Label Trial of STRIBILD(TM) (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naive HIV-2 Infected Adults in Dakar, Senegal

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
  • Indications HIV-2 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Stribild HIV-2
  • Most Recent Events

    • 25 May 2017 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
    • 04 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top